Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00628) | |||||
---|---|---|---|---|---|
Name |
Sitagliptin
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Sitagliptin; 486460-32-6; Januvia; MK-0431; Xelevia; Sitagliptin phosphate; UNII-QFP0P1DV7Z; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Tesavel; LEZ763; QFP0P1DV7Z; Sitagliptan; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; CHEBI:40237; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; 1,2,4-Triazolo[4,3-a]pyrazine,7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-; Sitagliptin (Prop.INN); Sitagliptin [INN:BAN]; sitagliptina; sitagliptine; sitagliptinum; Sitagliptin/; SR-05000001748; 790712-60-6; HSDB 7516; LEZ 763; Sitagliptin (13); PubChem18268; Tube110; Sitagliptin; MK0431; 1169707-31-6; EC 690-730-1; CHEMBL1422; SCHEMBL17783; BSPBio_002262; Triazolopiperazine Analogue 1; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; MLS006011959; GTPL6286; BDBM11162; C16H15F6N5O; DTXSID70197572; LEZ-763; HMS2093F20; ACT02665; EX-A2816; Sitagliptin (Metformin,MK-0431); ZINC1489478; ABP000233; MFCD09838015; AKOS015888724; CCG-268731; DB01261; MCULE-2101761133; PB17676; SB20299; NCGC00178734-03; NCGC00178734-06; 7-((3R)-3-Amino-1-oxo-4-(2,4,5-trifluorophenyl)buyl)-5,6,7,8-tetrahydro-3-trifluoromethyl)-1,4-triazolo(4,3-a); AS-19118; HY-13749; SMR002546724; SBI-0206871.P001; AB0006583; A14377; A25516; D08516; Q-1665; AB01563393_01; AR-270/43507782; Q419832; Q-101366; Q-201711; SR-05000001748-1; BRD-K19416115-001-01-2; BRD-K19416115-001-03-8; Z1541638523; (1R)-3-oxo-3-[3-(trifluoroethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorobenzyl)propylamine; (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-a; (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; (3r)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[3,4-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one hydrochloride; (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; 1,2,4-Triazolo(4,3-a)pyrazine, 7-((3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydor-3-(trifluoromethyl)-; 3-oxo-1-(2,4,5-trifluorobenzyl)-3-(3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)propylamine; 7-[(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Diabetes mellitus | ICD-11: 5A10 | [1] | ||
PubChem CID | |||||
Formula |
C16H15F6N5O
|
||||
Canonical SMILES |
C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N
|
||||
InChI |
1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
|
||||
InChIKey |
MFFMDFFZMYYVKS-SECBINFHSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=4369359"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 407.31 | Topological Polar Surface Area | 77 | |
XlogP | 0.7 | Complexity | 566 | ||
Heavy Atom Count | 28 | Rotatable Bond Count | 4 | ||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 10 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Sitagliptin 100 mg tablet | Click to Show/Hide the Full List of Formulation(s): 5 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycol
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Calcium hydrogenphosphate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Lake Eire Medical & Surgical Supply DBA Quality Care Products | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Calcium hydrogenphosphate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Cardinal Health; Clinical Solutions Wholesale | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Merck Sharp & Dohme | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Calcium hydrogenphosphate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 5 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | RemedyRepack | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Sitagliptin 50 mg tablet | Click to Show/Hide the Full List of Formulation(s): 3 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycol
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Calcium hydrogenphosphate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Avera McKennan Hospital; Cardinal Health; Merck Sharp & Dohme | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Calcium hydrogenphosphate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Cardinal Health | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Sitagliptin 25 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Avera McKennan Hospital; Merck Sharp & Dohme | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Calcium hydrogenphosphate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.